Sami Corwin
Stock Analyst at William Blair
(n/a)
# 4,455
Out of 4,869 analysts
12
Total ratings
16.67%
Success rate
-45.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sami Corwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | n/a | $20.08 | - | 1 | Jun 20, 2025 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Outperform | $65 | $37.14 | +75.01% | 1 | May 28, 2025 | |
| NKTX Nkarta | Downgrades: Market Perform | n/a | $1.77 | - | 1 | May 15, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Market Perform | n/a | $4.27 | - | 2 | Jan 30, 2025 | |
| APLT Applied Therapeutics | Downgrades: Market Perform | n/a | $0.34 | - | 1 | Dec 23, 2024 | |
| TNYA Tenaya Therapeutics | Initiates: Outperform | n/a | $0.59 | - | 1 | Jun 10, 2024 | |
| NGNE Neurogene | Initiates: Outperform | n/a | $17.81 | - | 1 | Mar 21, 2024 | |
| MESO Mesoblast | Downgrades: Market Perform | n/a | $10.44 | - | 1 | Aug 4, 2023 | |
| CRSP CRISPR Therapeutics AG | Reinstates: Outperform | $75 | $44.25 | +69.49% | 1 | May 30, 2023 | |
| LEGN Legend Biotech | Initiates: Market Perform | n/a | $34.00 | - | 1 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $66 | $14.21 | +364.46% | 1 | Oct 27, 2021 |
Sarepta Therapeutics
Jun 20, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $20.08
Upside: -
Ultragenyx Pharmaceutical
May 28, 2025
Initiates: Outperform
Price Target: $65
Current: $37.14
Upside: +75.01%
Nkarta
May 15, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.77
Upside: -
CARGO Therapeutics
Jan 30, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $4.27
Upside: -
Applied Therapeutics
Dec 23, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.34
Upside: -
Tenaya Therapeutics
Jun 10, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.59
Upside: -
Neurogene
Mar 21, 2024
Initiates: Outperform
Price Target: n/a
Current: $17.81
Upside: -
Mesoblast
Aug 4, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.44
Upside: -
CRISPR Therapeutics AG
May 30, 2023
Reinstates: Outperform
Price Target: $75
Current: $44.25
Upside: +69.49%
Legend Biotech
May 25, 2023
Initiates: Market Perform
Price Target: n/a
Current: $34.00
Upside: -
Oct 27, 2021
Initiates: Outperform
Price Target: $66
Current: $14.21
Upside: +364.46%